PEPTONIC medical AB (FRA:28L) PEG Ratio: 0.00 (As of Jul. 07, 2026)


What is PEPTONIC medical AB PEG Ratio?

PEPTONIC medical AB FRA:28L PEG Ratio is 0.00 as of Jul. 07, 2026. The stock has 6 warning signs investors should review. Among 349 Drug Manufacturers companies, PEPTONIC medical AB ranks worse than 286532.66% on this metric.

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, PEPTONIC medical AB's PE Ratio without NRI is 0.00. PEPTONIC medical AB's 5-Year EBITDA growth rate is 56.30%. Therefore, PEPTONIC medical AB's PEG Ratio for today is 0.00.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for PEPTONIC medical AB's PEG Ratio or its related term are showing as below:



FRA:28L's PEG Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.7
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


PEPTONIC medical AB  (FRA:28L) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


PEPTONIC medical AB PEG Ratio Related Terms


PEPTONIC medical AB PEG Ratio Historical Data

* Premium members only.

The historical data trend for PEPTONIC medical AB's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PEPTONIC medical AB PEG Ratio Chart

PEPTONIC medical AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PEPTONIC medical AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:28L vs ZTS, UTHR, VTRS: PEG Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PEPTONIC medical AB's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PEPTONIC medical AB PEG Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PEPTONIC medical AB's PEG Ratio distribution charts can be found below:

* The bar in red indicates where PEPTONIC medical AB's PEG Ratio falls into.



PEPTONIC medical AB PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

PEPTONIC medical AB's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/56.30
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Frequently Asked Questions Learn more about PEG Ratio →
What does a PEG Ratio of 0.00 mean?
PEPTONIC medical AB (FRA:28L) has a PEG Ratio of 0.00 as of Jul. 07, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on PEPTONIC medical AB and its competitors. According to the industry distribution chart, PEPTONIC medical AB ranks #999999 out of 349 companies in the Drug Manufacturers industry.
Is PEPTONIC medical AB's PEG Ratio too high?
PEPTONIC medical AB's current PEG Ratio is 0.00. Based on the distribution chart, PEPTONIC medical AB ranks #999999 out of 349 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does PEPTONIC medical AB's PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PEPTONIC medical AB ranks #999999 out of 349 companies for PEG Ratio. This places PEPTONIC medical AB in the lower half of its industry. The industry median PEG Ratio is 1.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.70, based on 349 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on PEPTONIC medical AB and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PEPTONIC medical AB's current PEG Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PEPTONIC medical AB stock overvalued right now?
PEPTONIC medical AB (FRA:28L) has a current PEG Ratio of 0.00. The current PEG Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For PEPTONIC medical AB (FRA:28L), the current PEG Ratio is 0.00 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PEPTONIC medical AB Business Description

Other Exchanges PMED:Sweden
Address Gustavslundsvagen 143, Bromma, SWE, SE-167 51
PEPTONIC medical AB is a pharmaceutical company. It is engaged in developing oxytocin-based products for the treatment of menopausal symptoms, such as vaginal atrophy and vaginal dryness. Oxytocin is for medical use and offers an alternative to estrogen and estrogen-like acting compounds for menopausal and postmenopausal women. The company is based in Sweden.